SYK and rheumatoid arthritis (RA) Archives

Abstract Number: 2518 • ACR/ARHP Annual Meeting 2018
GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study
Alan J. Kivitz¹, Daksha P Mehta², Franziska Matzkies³, Afsaneh Mozaffarian³, Rebecca Kunder³, Julie Di Paolo⁴, Neelufar Mozaffarian³, Sean Hsueh³, JiYun Kim⁵, Wendy Jiang³, Lin Liu³, John S. Sundy⁶ and Mark C. Genovese⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Center for Arthritis and Osteoporosis, Elizabethtown, KY, ³Gilead Sciences, Inc., Foster City, CA, ⁴Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA, ⁵Biomarkers, Gilead Sciences, Inc., Foster City, CA, ⁶Clinical Research, Inflammation and Respiratory, Gilead Sciences, Inc., Foster City, CA, ⁷Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling and is essential in activation of cells including B lymphocytes, monocytes, macrophages, dendritic cells, and osteoclasts. SYK…
Abstract Number: 1621 • ACR/ARHP Annual Meeting 2016
A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Hmpl‑523 in Australian Male Healthy Subjects
Jason Lickliter¹, Yan Wu², Ye Hua², Irena Yuan², Guangxiu Dai², Xiong Li², Jian Wang², Yang Sai², Zhongcui Sun², Angela Pan², Jing Li² and Weiguo Su², ¹Nucleus Network, Melbourne, Australia, ²Hutchison MediPharma Limited, Shanghai, China
Background/Purpose: Spleen Tyrosine Kinase (SYK) plays a pivotal role in the regulation of downstream signals in immune receptors, including B cell receptors (BCRs), which…

Abstracts tagged "SYK and rheumatoid arthritis (RA)"

GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study

A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Hmpl‑523 in Australian Male Healthy Subjects